Acute Effect of Aliskiren on Smoking-Induced Endothelial Dysfunction in Smoker
Main Article Content
Abstract
Background: We aimed to examine the acute effect of aliskiren on smoking-induced endothelial dysfunction in smoker.
Methods: Nineteen male smokers were enrolled. After all participants smoked a cigarette, their endothelial function was assessed with brachial artery flow mediated dilation (FMD). An hour after the administration of aliskiren, they smoked again, their FMD was assessed again. A month later, all measurements were performed again without the administration of aliskiren as a control. Blood pressure, plasma renin activity, and serum interleukin-6 concentration were also examined at the same time of FMD measurement.
Results: A cigarette smoking led to an acute endothelial dysfunction (6.5 ± 1.7% to 3.4 ± 1.0 %, P = 0.02). Aliskiren administration significantly suppressed blood pressure and plasma renin activity, furthermore, improved FMD (6.7 ± 0.5% to 8.1 ± 0.8 %, P = 0.03). Aliskiren significantly reduced serum interleukin-6 concentration, but not in control.
Conclusion: Aliskiren has a beneficial effect on smoking-induced acute endothelial dysfunction.
Downloads
Article Details
Copyright (c) 2014 Uchida HA, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Santo-Tomas M, Lopez-Jimenez F, Machado H, Aldrich HR, Lamas GA, et al. (2002) Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults. Am Heart J 143: 83-86.
Esen AM, Barutcu I, Acar M, Degirmenci B, Kaya D, et al. (2004) Effect of smoking on endothelial function and wall thickness of brachial artery. Circ J 68: 1123-1126.
Karatzi K, Papamichael C, Karatzis E, Papaioannou TG, Stamatelopoulos K, et al. (2007) Acute smoke-induced endothelial dysfunction is more prolonged in smokers than in non-smokers. Int J Cardiol 120: 404-406.
Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, et al. (2009) Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120: 502-509.
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, et al. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.
Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, et al. (2009) Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119: 530-537.
McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, et al. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1: 17-24.
Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, et al. (2009) Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32: 1873-1879.
Ogawa S, Nako K, Okamura M, Senda M, Mori T, et al. (2011) Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res 34: 400-401.
Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM, et al. (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377: 312-320.
Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K, et al. (2008) Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 30: 267-276.
Tezcan H, Yavuz D, Toprak A, Akpinar I, Koc M, et al. (2003) Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. J Renin Angiotensin Aldosterone Syst 4: 119-123.
Tomiyama H, Yamashina A (2010) Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 74: 24-33.
Ciftci O, Gunday M, Caliskan M, Gullu H, Guven A, et al. (2013) Light cigarette smoking and vascular function. Acta Cardiol 68: 255-261.
Amato M, Frigerio B, Castelnuovo S, Ravani A, Sansaro D, et al. (2013) Effects of smoking regular or light cigarettes on brachial artery flow-mediated dilation. Atherosclerosis 228: 153-160.
Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, et al. (2010) Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 55: 1988- 1995.
Liu PY, Lin CC, Tsai WC, Li YH, Lin LJ, et al. (2008) Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers. J Thromb Haemost 6: 1685-1692.
Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, et al. (2010) Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J 74: 195-202.
Kim KS, Park HS, Jung IS, Park JH, Ahn KT, et al. (2011) Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment. J Cardiovasc Ultrasound 19: 21-25.
Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, et al. (2008) A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 46: 252-258.
Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M, et al. (2004) Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis 172: 259-265.
Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, et al. (2007) Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 20: 392-397.
Siasos G, Tousoulis D, Vlachopoulos C, Antoniades C, Stefanadi E, et al. (2009) The impact of oral L-arginine supplementation on acute smoking- induced endothelial injury and arterial performance. Am J Hypertens 22: 586- 592.
Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, et al. (2008) Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31: 776-782.
Dong YF, Liu L, Kataoka K, Nakamura T, Fukuda M, et al. (2010) Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 53: 180-191.
Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, et al. (2008) Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 52: 563-572.
Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, et al. (2008) Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 149: 5643-5653.
Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, et al. (2011) A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219: 734-736.
Antoniades C, Demosthenous M, Tousoulis D, Antonopoulos AS, Vlachopoulos C, et al. (2011) Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 58: 93-98.